CSTL
HealthcareCastle Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving CSTL Today?
No stock-specific AI insight has been generated for CSTL yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
CSTL News
20 articles- Castle Biosciences, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Castle Biosciences Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Castle Biosciences Reports First Quarter 2026 ResultsYahoo Finance·May 6, 2026
- Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock RisesYahoo Finance·May 6, 2026
- OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookYahoo Finance·May 6, 2026
- EDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusYahoo Finance·May 6, 2026
- Repligen's Q1 Earnings & Revenues Beat Estimates, Stock RisesYahoo Finance·May 6, 2026
- JAZZ Stock Jumps as Q1 Earnings & Sales Surpass ExpectationsYahoo Finance·May 6, 2026
- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in FocusYahoo Finance·May 5, 2026
- AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity SalesYahoo Finance·May 5, 2026
- Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should KnowYahoo Finance·May 5, 2026
- CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesYahoo Finance·May 5, 2026
- Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness MonthYahoo Finance·May 5, 2026
- New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's EsophagusYahoo Finance·May 4, 2026
- KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD CollaborationYahoo Finance·May 1, 2026
- AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug MomentumYahoo Finance·Apr 30, 2026
- Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/YYahoo Finance·Apr 30, 2026
- VKTX Q1 Earnings Miss on Higher Phase 3 Development CostsYahoo Finance·Apr 30, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Castle Biosciences Inc
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.